Search

everythinglearnresearchcommunity

for

Search:↓

Redensyl is being compared to Minoxidil for hair loss treatment. Users discuss the effectiveness of Redensyl versus Minoxidil, with no clear consensus on which is better.

Kintor is accused of using fake pictures to promote their product, Pyrilutamide (KX826), which failed Phase 3 trials. Users express disappointment and note similar false advertising has occurred with finasteride and minoxidil.

The conversation discusses skepticism over the results of Pyrilutamide for hair regrowth, suggesting that results from rigorous trials are more trustworthy. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

A user shared a 6-month hair loss treatment routine including Mexican finasteride (1.25mg every other day), daily minoxidil, bi-weekly dermarolling, and ketoconazole shampoo twice a week, noting significant crown growth and some frontal hairline improvement with initial side effects that have since subsided. They are seeking advice to improve results, particularly at the frontal hairline, without resorting to a hair transplant.

Mixing RU58841 with cetosomal minoxidil is discussed due to scalp irritation from ethanol PG vehicles. A mixture of the two turned bright pink when left to dry.

The conversation discusses hair loss treatments, specifically using dutasteride (0.5mg daily) with no side effects reported after two months. It also mentions the health benefits of one meal per day and the low incidence of side effects.

A user is concerned about using Alpicort, which contains Prednisolone and Salicylic Acid, for male pattern baldness. They are unsure if it will help or worsen their condition and are seeking advice.

The user's consideration of taking finasteride as a short-term treatment, while awaiting advances in medical technology such as Pyrilutamide and GT20029; other users' experiences with Finasteride, including potential side effects.

Pyrilutamide and RU58841 are androgen receptor antagonists that block receptors without significantly reducing testosterone or DHT levels. Any indirect effect on androgen levels is likely negligible.

The conversation is about someone inquiring if anyone has tried Olumiant or its active ingredient, Baricitinib, for hair loss, mentioning the cost and that they have ordered Baricitinib.

An 18-year-old is using a high-dose hair loss treatment regimen including finasteride, minoxidil, dutasteride, and plans to add RU58841 and bimatoprost, despite warnings from others about the risks. The user is determined to reverse hair loss but acknowledges the potential dangers and does not recommend others follow their approach.

The conversation discusses the difference between the commercially available Pyrilutamide and the version in clinical trials. It also mentions treatments like Minoxidil, finasteride, and RU58841 for hair loss.

A user's 11-month hair loss treatment progress using 0.5mg dutasteride every other day, 50mg RU58841 in the morning, 5mg oral minoxidil, topical minoxidil at night, and microneedling with a 1.5mm needle every other week. The user's improvement was significant, going from a severe hair loss stage (NW7) to a mild/moderate stage (NW2-3).

The user is experiencing diffuse androgenic alopecia and is trying various treatments, including 5mg finasteride, loniten, and Formula 82D, which contains dutasteride, a steroid, and tretinoin. They report potential regrowth with Formula 82D, despite previous treatments being ineffective.

Stemoxydine, a hair loss treatment, is reportedly discontinued, with some users suggesting alternatives like a rebranded version with resveratrol that may enhance Minoxidil. Some users express dissatisfaction with the discontinuation and question the product's value.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115, a monoclonal antibody drug, is in phase 1 and 2 trials for different conditions, but its availability on the gray market is unlikely due to high production costs.

Redensyl improved hair thickness slightly with no side effects, but no regrowth. Minoxidil provided significant regrowth but caused facial side effects like puffiness.

The user is concerned about the safety of combining 4mg oral Minoxidil, 450mg caffeine, and 6 hours of intense weight lifting. They are seeking reassurance that this combination won't be harmful.

Aminexil is similar to Minoxidil but less effective and not widely used, with some users reporting minor regrowth. It is not FDA-approved and has been removed from some products, though some people still use it, often in combination with Minoxidil.

A 19-year-old transgender individual is experiencing worsening temple recession despite taking female hormones and 1.25mg finasteride. They are seeking advice on additional treatments to address hair loss.

Kintor Pharma announced successful Phase II trial results for KX-826 in treating hair loss, showing it's comparable to finasteride and can be used with it. Some participants saw a 10 hair/cm^2 increase, which is considered a good outcome at the low dose used.

AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.

A 23-year-old male experienced no shedding with RU58841 but switched to oral finasteride due to heart concerns, resulting in increased hair shedding. He is considering adding minoxidil to his regimen, which currently includes finasteride, Nizoral shampoo, and microneedling.

Clascoterone has shown promising results in increasing hair density without systemic side effects, potentially offering benefits similar to finasteride. There is skepticism due to the lack of published photos despite the market interest.

The user is treating hair loss with a regimen including Dutasteride, oral and topical Minoxidil, microneedling, and various supplements for overall health. They are considering adding tretinoin, stemoxydine/RU, DIM, Boron, and Fadogia Agretis to their routine.

A user with seborrheic dermatitis uses Ketoconazole 2% and Betamethasone and is considering starting Minoxidil for thinning hair. They are concerned about using Minoxidil and Betamethasone simultaneously.

The user has been using oral minoxidil at 10 mg daily, split between morning and night, alongside finasteride for 7 years, and reports new hair growth at the temples. Many users express concern over the high minoxidil dosage, citing potential health risks, while others question the effectiveness and necessity of such a dose.

Spironolactone and finasteride are not recommended for women planning pregnancy due to birth defect risks. Both need to be stopped months before conception, and finasteride is generally not advised for women.

Oral minoxidil has shown positive results for hair regrowth, but concerns about its side effects, such as heart issues, are noted. Adding a DHT blocker like finasteride is recommended for better and more lasting results.

The conversation discusses the effectiveness of RU58841 for hair loss compared to pyrilutamide, which failed to show significant hair regrowth in trials. Some users report personal side effects with RU58841 and question the criteria for success in hair loss treatments.